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A novel. Bis-indolylmaleimide. Ro 31-8425, bearing a conformationally restricted side chain, inhibits protein kinasc C isolated from rat brain and 
human neutrophils with a high degree of selectivity over CAMP-dependent kinase and Ca’-/calmodulin-dependent kinase. It also inhibits phorbol 
ester-induced intracellular events known to be mediated by protein kinase C (p47 phosphorylaticn in intact platelets. CD3 and CD4 down-regulation 
in T-cells). Ro 31-8425 inhibited supcroxide generation in human neutrophils activated by both receptor stimuli (formyl-methionyl-leucyl- 
phcnylalanine. opsonized zymosan. IgG and heat aggrcgatcd IgG) and post-receptor stimuli (I .2-dioctanoylglycerol and fluoride). The compound 
also blocked antigen driven, but not IL-2 induced, T-cell proliferation. These results support a central role for protein kinase C in the activation 
of the respiratory burst and antigen-driven T-cell proliferation. 
Neutrophil: Supcroxide: Protein kinase C; Opsonized zymosan; T-Cell proliferation: Interleukin-2 
1. INTRODUCTION 
Neutrophils activated by chemotactic or phagocytic 
stimuli increase their oxygen uptake and produce co- 
pious amounts of superoxide (0;). the precursor of 
powerful microbicidal oxidants [I 1, This neutrophil ‘re- 
spiratory burst’ has been implicated in the pathogenesis 
ofseveral diseases [2,3]. The stimulus-response pathway 
operating in the neutrophil respiratory burst has not yet 
been fully elucidated. One pathway may involve the 
hydrolysis of phosphatidylinositol bisphosphate (PIP,) 
by a receptor-linked pllospholipase C to give inositol 
trisphosphate (IP,), which mobilizes intracellular Ca” 
and diacylglycerol (DAG). which activates protein 
kinase C (PKC) [4]. However. a second prolonged phase 
of DAG production, independent of PIPI! hydrolysis, 
may be required to sustain the respiratory burst [5]. This 
DAG may be produced by the action of a receptor- 
linked phospholipase D oil phosphatidylcholine to yield 
Ahhrc~‘ictrictrr.c~ Oz. supcroxidc; DAG, diacylglyccrol; DiC,. dioc- 
tanoylglyccrol: fMLP. fornlyl-mcthionyl-Icucyl-phcllyl-alalc~ IP,, 
inositol !risphosphatc; PDBu. phorbol dibutyratc: PIP?. phosphatidyl- 
inositol hisphosphatc: PLC. phospholipasc C: PLD. phospholipasc D: 
PKA. protein kinasc A: PKC. protein kinasc C: TPA. l2-O-tctradc- 
canoylphorbol 1%acctatc. 
Cor!,c’,s/~“‘rrl~f’lr~~~ crr/tbc.rs: J.S. Nixon. Rcscurch Ccntrc. Rochc Pro- 
ducts Ltd.. Bro:idwatcr Ro;ld. Wclwyn Ciardcn City. AL7 3AY. En- 
gl;LIld. VU: (44) (70’7) 373 504. 
phosphatidic acid which is subsequently hydrolysed by 
phosphatidate phosphatase [6-81. The operation of 
these pathways indicates that increased DAG levels, 
however derived, and subsequent PKC activation are 
involved in 01 generation. This is supported by the obser- 
vation that stimulants of the 0; burst such as fMLP and 
leukotriene B4 will cause translocation of PKC from the 
cytosol to the membrane [9]. 
Despite this, the role of PKC in receptor-mediated 01 
production is unclear. The arguments against PKC in- 
volvement in this process stem from 2 sources. First, 
activation of the respiratory burst by fMLP correlates 
with formation of phosphatidic acid rather than conver- 
sion of phosphatidic acid to DAG [IO]. Second. the 
isoquinoline sulphonamide PKC inhibitor, H7, dces not 
suppress the fh4LP-induced burst [ 1 I, 121. However, H7 
does not inhibit a range of phorbol ester mediated 
events in cells and its value as a tool to probe for PKC 
involvement in cellular processes is questionable [13]. 
Additionally, the results seen with H7 were not support- 
ed by those obtained with staurosporinc. This potent 
but non-selective PKC inhibitor blocked 0; generation 
induced by a variety of mediators [14]. 
A series of potent and selective his-indolyl-maleimide 
inhibitors of PKC, structurally related to staurosporine 
and cxemplificd by Ro 31-7549 (Fig. 1) have recently 
been reported [ 151. Ro 31-7549 was a potent inhibitor 
of the neutrophil respiratory burst triggered by a range 
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of soluble agonists but failed to block the response to 
opsonized zymosan (OZ) [ 161. Conformational restric- 
tion of the amine-bearing side chitin in Ro 31-7549 has 
resulted in Ro 31-8425 (Fig. l), an analogue with im- 
proved potency and selectivity for PKC. This agent in- 
hibits human neutrophil 0, generation stimulated with 
soluble agonists (dioctanoylglycerol (diC&, formyl-me- 
thionyl-leucyl-phenylalanine (fMLP). fluoride and with 
particulate stimuli such as IgG. heat-aggregated IgG 
and OZ. 
2. MATERIALS AND METHODS 
2.1, Inlribition of PKC Cr vitro 
Rat brain PKC and human ncutrophil PKC were partially purified 
by ion-exchange chromatography and assayed according to the 
method described in [ 151. 
2.2. lnlribiriori of PKA in vitro 
Bovine heart PKA was assayed according to the method described 
in [1.5]. 10 ~1 human neutrophil PKA. partially purified by ion-ex- 
change chromatography, were added to a reaction cocktail (90 ~1) 
containing 0.67 mg/ml histone (type VS). I I PM CAMP. inhibitor in 
IO fll DMSQ and I1 flbl [y-“‘P]ATP in 50 mM Tris-HCI. 10 mM 
MgCL, pH 7.5. After I5 min incubation at 30°C the assay procedure 
ik<tcafter was thut described fo; PKC [15]. 
2.3. bthibirion of Cu”/catfFiod~ttirl-dc,~ctl~ict~t porch kimw if! l’ilr’o 
Ca’+/calmodulin-dcpcndent protein kinasc. partially purified from 
rat brains. we assayed according to the method described in [15]. 
2.4. itrhibitiorr of rubbi! rmscle plrosphor~~law kihase in vitro 
Rabbit musc!c phosphorylase kinase was assayed by the method 
described in [17]. 
2.5. TPA-irrdrcced ~47 phosphor_vla/ion in intacr plarelm 
The elTects of inhibitors on TPA-induced p47 phosphorylation in 
platelets freshly isolated from human blood were measured by the 
method described in [IS]. 
2.6. PDBrc-induced CD3 muI CD4 dowrr~gubrivn irr T-cells 
The inhibition of down-regulation of CD3 and CD4 induced in 
freshly prepared human peripheral blood mononuclear cells by phor- 
bol dibutyrate (PDBu) was assycd by the method described in [15]. 
Mixed lymphocyte reactions were performed by the method of 
Fitzharris and Knight [l8]. 
2.8. IL-Xttdrrced T-cell prol$ercrriotl 
CD2-positive T-lymphocytes were isolated from peripheral blood 
taken from healthy human volunteers and sccdcd in 96-well plates at 
a concentration of 3x1@ cells per well. The cells were incubated in the 
presence of phorbol ester for 48 h. after which 10 U/ml human rccom- 
bitant IL-2 and inhibitor were added. The appropriate solvent-only 
controls were included in each experiment. The cells were incubated 
for a further 24 h. The uptake of pH]thymidinc over a subsequent 8 
h time period was then measured and used as an indication of the 
proliferative response. 
2.9. Nerc/ro/)lril wperosi~le f 4,) os.sq~ 
Ncutrophils were prcparcd from human blood and suspended in the 
appropriate buffer as described [ 141. The ncutrophils wcrc equilibrated 
for 20 min at 37°C; to those cells which wcrc to bc stimulated with 
fMLP. cytochalasin B (5 pdml) was added. Assay tubes contained 1 
mg fcrricytochromc c (horse heart type III). inhibitor at the appro- 
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Fig. I. Structure of PKC inhibitiors. 
priate concentration or buffer solution, either buffer or 75 U superox- 
idc dismutasc (bovine blood) and 2 x i06cells. Pre-incubation with the 
drug was continued for a further 5 min before the addition of sti- 
mulant. After 30 min at 37°C (60 min for IgG), the reaction was 
stopped by the adition of 1 mM N-ethyhnalcimide. Following centri- 
fugation at 1400 xg for IO min at 4’C, the absorbance of the superna- 
tant was read spectrophotometrically and r.mol 0; produced was 
calculated as previously described [14]. OZ and heat-aggregated IgG 
were prepared as dcscribcd in [19]. 
Results from each separate experiment were normalised. expressing 
each value for 01 production as a percentage of the maximum 
control response (in the absence of inhibitor) obtained in that parti- 
cular experiment. The means with standard errors from scvcral cxperi- 
ments wcrc calculated and displayed graphically from which the IC,,, 
values were obtained. 
All drugs. at concentrations used, had no effect on ccl! viability as 
assessed by Trypan blue exclusion and lactate dchydrogcnase assays. 
3. RESULTS AND DISCUSSION 
The aminopropyl bis-indolyl maleimide, Ro 3 l-7549, 
is a potent inhibitor of rat brain and hurnan neutrophil 
PKCs. A further IO-fold potency improvement was ob- 
tained by conformational restriction of the primary 
amine at specific spatial positions relative to the bis- 
indolylmaleimide. The most potent of these inhibitors, 
Ro 31-8425, showed a 250-fold selectivity for human 
neutrophil PKC over PKA and a 2500-fold selectivity 
for rat brain PKC over Ca’+/calmodulin-dependent 
protein kinase (Table I). This represents a significant 
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Table I Table II 
Inhibitor ICsO values (uM) against isolated protein kinases Inhibitor I&, values @M) in cellular systems 
Ro 3 l-8425 Ro 3 l-7549 Ro 31-8425 Ro 31-7.549 
- - 
Inhibirion of pkorbol ester-in 
duced events 
p47 protein phosphorylati:>n 0.46kO.26 (n=3) 4.4Ok2.41 (n=IO) 
in’platelets 
CD3 down-regulation in T-cells 0.6kO.3 (n=3) 3.820.8 (n=3) 
CD4 down-regulation in T-cells 0.08?0.01 (~=3) 5.3k2.0 (n=3) 
Rat brain PKC 0.007640.001 (n=lO) 0.075+0.019 (n= 17) 
Human neutrophil PKC 0.0048~0.0015 (n=6) 0.048+0.013 (n=6) 
Bovine heart PKA 2.84+ I .22 (n=6) 5.05+1.43 (n=7) 
Human neutrophil PKA 1.20+0.49 (~5) 4.2 (n=2) 
Rat brain Ca”/CAM- 19.0 (n=2) 15.0 (n=2) 
dependent kinase 
Rabbit muscle phos- 1.27-tO. I 5 (n=3) 0.84kO.24 (n=6) 
nhorvlase kinase 
improvement in selectivity profile over that of Ro 31- 
7549. 
Phorbol esters, potent and direct activators of PKC, 
were used to demonstrate the PKC inhibitory activity 
of Ro 31-7549 and Ro 31-8425 in cells (Table II). Ro 
3 I-8425 was a more potent inhibitor of a range of phor- 
bol ester driven processes than Ro 31-7549, in line with 
their relative inhibitory activities against isolated PKC. 
ATPconcentrations in cells are much higher (l-10 mM) 
than that used in the isolated enzyme assay (10,~M) and 
this probably contributes to the reduced potencies of 
these ATP-competitive inhibitors in intact cell systems. 
Since PKA often antagonises the effects of PKC in 
the neutrophil and in the T-lymphocyte, data obtained 
with non-selective inhibitors such as staurosporine [20] 
and K252a [21] are difficult to interpret. The high de- 
gree of selectivity shown by Ro 31-8425 for PKC over 
PKA makes this an appropriate tool to probe for PKC 
involvement in the neutrophil respiratory burst and in 
T-cell proliferation. 
When studying neutrophil0; generation, 2 concentra- 
25 
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NO ORUG 0.1 1 10 
Ro31-8425 (+LM) 
hhibition of T-cell prolt+rotion 
Mixed lymphocyte reaction 0.47kO.43 (n=4) 2.OkO.7 (n=S) 
IL-2-induced proliferation > 10.0 (n=2) not deterrnincd 
tions of each stimulant were selected which produced 
between 20-100 % maximal response. Dose-inhibition 
curves were produced for Ro 31-8425 at both concen- 
trations of agonist (Fig. 2A). In all cases, I&, values did 
not alter with stimulant concentration. 
Ro 31-8425 inhibits the neutrophil respiratory burst 
induced by a variety of soluble and particulate agents 
implying the involvement of PKC in the signal trans- 
duction mechanisms stimulated by all these agents 
(Table III). The respiratory burst triggered by diCs, a 
direct PKC activator, was more sensitive to inhibition 
by Ro 31-8425 than were the responses induced by 
fML.P, IgG, heat aggregated IgG and OZ. This suggests 
that PKC activation is involved in transduction of the 
signal invoked by this second group of agonists, but it 
is not the rate-limiting step in these pathways. These 
mediators may bind to more than one class of receptor, 
initiating both PKC-dependent and indepenent path- 
ways, but this seems unlikely since almost complete 
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100 
25 
0.1 0.3 1 3 
Opsonized zymoson (mg ml-‘) 
Fig. 2. The effects of Ro 3 I-8425 on opsonizcd zymosan-stimulated superoxidc generation. Results arc cxprcssed as % mean maximum supcroxide 
produced by opsonized zymosan alouc (25.4k2.5 nmol per IO6 cells in A. 29.3k2.2 nmol per IO’ cells in B). (A) Concentration-inhibition curves: 
(o), Opsonized zytnosan control at 3 m@ml (u), with Ro 318425; (r~), control at 0.3 mdmt and (u). with Ro 31-8425. (B) Concentration-rcsponsc 
curves: (Q)), Opsonizcd zymosan itlone. (o), with Ro 31-8425 at 0.1 ,uM. (w), with Ro 31-8425 at 3 PM. All data points rcprcscnl mcan?SE (A: 
tr=4; B: n=3). 
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Table III 
Inhibitor lCs,, values WM) with stimulated ncutrophil supcroxide 
generation 
Stimulus Receptor Ro 31-8425 
Fluoride G-protein 0.005+0.001 (n=4) 
diCs PKC 0.148+0.006 (n=4) 
t-MLP TMLP 0.60 f0.05 (11~5) 
Heat aggregated IgG Fey I.29 kO.06 (rr=4) 
Opsonizcd zymosan FcylC3bliC3b 2.84 co.09 (rr=4) 
w Fey 3.65 kO.13 (rr=S) 
inhibition of the response to these agents was achieved 
with Ro 31-8425. 
The fluoride-induced burst was some 30-fold more 
sensitive to inhibition by Ro 31-8425 than the burst 
induced by the direct PKC activator. diC,. This profile 
has been noted with other his-indolyl maleimides and 
staurosporine [I61 and may result from a reduction in 
intracellular ATP concentration caused by fluoride [22]. 
or may indicate a differential sensitivity of these agents 
to different PKC isoforms. 
Ro 31-8425 showed a biphasic effect on the OZ-in- 
duced respiratory burst; low concentrations of Ro 31- 
8425 were slightly stimulatory, higher concentrations 
were inhibitiory (Fig. 2B). This biphasic effect was no- 
ticeable only at high concentrations of OZ (>0.3 mg/ml) 
and may result from a differential sensitivity of the 2 
PKC-dependent mechanisms to inhibition by Ro 31- 
8425. One pathway may activate the burst. the other 
may constitute a negative-feedback mechanism inhibit- 
ing the activation pathway. If PKC were rate-limiting 
in the feedback control mechanism. low levels of Ro 
31-8425 could selectively remove the feedback control 
without affecting the activation pathway. There are pre- 
cedents for a dual role for PKC in other cellular res- 
ponses, notably antigen-driven T-cell proliferation. 
Antigen-driven T-cell proliferation may be regarded 
as a 2 stage process. In the first stage. the antigenic 
signal delivered via the T-cell receptor-CD3 complex 
results in increased surface expression of the IL-2 recep- 
tor and in production of IL-2 [23]. In the second stage, 
binding of IL-2 to its receptor triggers cell division [24]. 
Inhibition of the allogeneic mixed lymphocyte reaction 
by Ro 31-8425 suggests a role for PKC in antigen driven 
T-cell proliferation. Ro 31-8425 had little effect on IL-2 
induced T-cell proliferation, suggesting that involve- 
ment of PKC in antigen driven proliferation occurs 
prior to IL-2 production, 
In conclusion, these results suggest that PKC is a 
common element in the respiratory burst signallinp 
pathways triggered by a wide range of stimulants ~-gag- 
ing different receptors. PKC also appears to play a key 
role in antigen-driven T-cell proliferation. Inhibition of 
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PKC. therefore, o.ffers potential for the treatment of 
both inflammatory and immunomodulatory disorders. 
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